Global /Sweden /Healthcare /Medical Devices /GENO
chevron_leftBack
Genovis AB (publ.) logo

Genovis AB (publ.)

GENO
STO: GENO Delayed
18.92SEK -2.3%
2.00 USD
As of 8 June 2026, Genovis AB (publ.) has a market cap of $136.45M USD, ranking #23459 globally and #301 in Sweden. It ranks #2108 in the Healthcare sector, and #438 in the Medical Devices industry.
Global Rank
23459
Country Rank
301
Sector Rank
2108
Industry Rank
438
Key Stats
Market Cap
$136.45MUSD
1.28B SEK
Enterprise Value
$125.5MUSD
1.19B SEK
Revenue (TTM)
$14.28MUSD
133.84M SEK
EBITDA (TTM)
$3.31MUSD
31.37M SEK
Net Income (TTM)
$2.59MUSD
24.3M SEK
EBITDA Margin
23%
Profit Margin
18%
PE Ratio
52.6
Forward PE
46.4
PS Ratio
9.6
PB Ratio
4.6
EV/EBITDA
31.2
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Medical Devices
CEO
Fredrik Olsson open_in_new
Employees
36
Founded
1999
Website
genovis.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
-2.3% -6.1% 11% -16% -17% -20%

News

Loading...

Markets

Exchange Ticker Price
Nasdaq Stockholm
MIC: XSTO
PRIMARY
GENO
Genovis AB
ISIN: SE0002485979
Shares Out.:
66.063M1 Shares Float: 51.919M2
TV:
SA:
YF:
GF:
BA:
MS:
18.92 SEK
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Genovis AB (publ.)

Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology; TransGLYCIT, a platform technology; and GingisREX, a protease that digests proteins C-terminally of arginine residues. In addition, the company offers OmniGLYZOR, a mixture of immobilized enzymes; PNGase F, a glycoamidase; OpeRATOR, an O-glycan-specific protease; ImpaRATOR, an O-glycan-dependent protease; OglyZOR, an endoglycosidase; SialEXO, a sialidase product; FucosEXO, a mix of α-Fucosidases; GalactEXO, a β-Galactosidase mix; GalNAcEXO, an α-N-Acetylgalactosaminidase; and GlycOCATCH, an affinity resin. Further, it provides GlycINATOR (EndoS2), an IgG-specific endoglycosidase; IgGZERO (EndoS), an IgG-specific endoglycosidase; Anti-FabRICATOR (Anti-IdeS), a family of antibody products; and Anti-FabRICATOR Z (Anti-IdeZ), a goat polyclonal antibody, as well as SEQURNA RNase Inhibitor Thermostable. Additionally, the company offers antibodies, proteins, antigens, kits, and cell culture products; bioprocess and gene therapy services; and services, such as SmartEnzymes fragmentation and conjugation, antibody LC-MS analysis, and customized antibody services. It serves biotech and pharmaceutical, contract research, and contract manufacturing companies. The company was founded in 1999 and is headquartered in Kävlinge, Sweden.

Similar Companies

Industry: Medical Devices (Sweden)
Name
Market Cap diff.
PE
GETI-B
$5.59B
52.4B SEK
4K%
22.2
S
SCIB
$4.85B
45.5B SEK
3K%
-
EKTA-B
$2.23B
20.86B SEK
2K%
-
$1.59B
14.87B SEK
1K%
-
$1.53B
14.32B SEK
1K%
78.5
$907.38M
8.5B SEK
565%
115.1
Industry: Medical Devices (Global)
Name
Market Cap diff.
PE
$173.27B
127K%
25.8
$160.73B
118K%
56.7
$159.07B
116K%
25.6
DHR
$126.55B
93K%
34.7
SYK
$120.69B
88K%
38.3
MDT
$101.9B
75K%
22.2
chevron_leftBack